Clinical Trials on Microsatellite Instability-High (MSI-H) Solid Tumors

Total 106 results

Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H Tumors

United States
BeiGene

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors

China
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Belgium, Spain, Canada, Denmark, United Kingdom
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor

China
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

MSI-H/dMMR Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

MSI-H or dMMR Advanced Solid Tumors

China
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor

France, Germany, Italy, Netherlands, Sweden, United Kingdom, Brazil, Israel, Korea, Republic of, United States
Sultan Abdulhamid Han Training and Research Hospital...

Completed

Microsatellite Instability in Colorectal Cancers (MSI-CRC)

Colorectal Cancer | Colorectal Carcinoma | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Instability-High

Turkey
Peking University Cancer Hospital & Institute

Recruiting

Registry Study in MSI/dMMR Solid Tumors

Solid Tumor | MSI-H | DMMR Cancer

China
Dan Zandberg

Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Melanoma | Hepatocellular Carcinoma | NSCLC | Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Urothelial Cancer | HNSCC | Microsatellite Instability-High Solid Malignant Tumor

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Active, not recruiting

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

High Tumor Mutation Burden | High TMB (Tumor Mutation Burden) | MSS (Microsatellite Stable)

United States
University of Utah
Elevar Therapeutics

Terminated

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE)

Urothelial Carcinoma | Advanced Malignancies | Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | MSI-H or dMMR Solid Tumors

United States
National Taiwan University Hospital

Unknown

A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer

Stage II Colon Cancer | MSI-L/MSS

Taiwan
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

MSI Positive Colorectal Cancer | MSI Negative Colorectal Cancer | MSI Positive Non-Colorectal Cancers

United States
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Yonsei University
Merck KGaA, Darmstadt, Germany

Active, not recruiting

K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

PD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation Tumor

Korea, Republic of
Apollomics (Australia) Pty. Ltd.
Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...

Completed

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Solid Tumor | Microsatellite Instability | Mismatch Repair Deficiency | Cancer of Unknown Primary Site

Australia
Federation Francophone de Cancerologie Digestive

Recruiting

Prospective Cohort Study of Immunotherapy Resistance in Metastatic Colorectal Cancer Patients With MSI (CORESIM)

Colorectal Cancer Metastatic | Microsatellite Instability-High Colorectal Cancer

France
University of Colorado, Denver
National Cancer Institute (NCI); Cancer League of Colorado

Withdrawn

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Colorectal Cancer | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Sun Yat-sen University
The Second Affiliated Hospital of Kunming Medical University

Completed

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Colorectal Cancer Metastatic | Microsatellite Instability High | Mismatch Repair Deficiency

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; Bayer

Active, not recruiting

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Colon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer

United States
Incyte Corporation

Recruiting

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Melanoma | Hepatocellular Carcinoma (HCC) | Renal Cell Carcinoma (RCC) | Colorectal Carcinoma (CRC) | Microsatellite Instability - High (MSI-H) | Mismatch Repair Deficient (dMMR)

United States, Brazil, Canada, Australia, Slovakia, Sweden, Norway, Mexico
Emory University
National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health...

Active, not recruiting

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)

Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | RAS Wild Type | MSI-H Colorectal Cancer | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma

United States
ImmuneOncia Therapeutics Inc.

Not yet recruiting

A Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)

TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
NextCure, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer | Advanced or Metastatic Solid Tumors | Microsatellite Instability Low | Microsatellite Instability High | Microsatellite Stable | Head Neck Cancer

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Novartis Pharmaceuticals

Recruiting

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

Japan, Spain, Singapore, Belgium, Germany, Korea, Republic of, Taiwan, France, Israel, United States
Synthekine

Recruiting

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Microsatellite Instability High | Malignant Melanoma | GastroEsophageal Cancer | Mismatch Repair Deficiency

United States
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Active, not recruiting

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Hepatocellular Carcinoma | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Microsatellite Instability-High

United States, Canada
Astellas Pharma Global Development, Inc.

Completed

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Advanced Solid Tumors | Pharmacokinetics of 14C-OSI-906

United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
University of Zurich

Terminated

PET/MRI Perfusion and CT Perfusion in Solid Tumors (Perfusion)

CT Perfusion and MRI Perfusion in Solid Tumors

Switzerland
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

High-Frequency Microsatellite Instability | Mismatch Repair Gene Mutation | Mutation-Negative Lynch Syndrome | Mutation-Positive Lynch Syndrome

United States
Emory University

Terminated

Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors

Recurrent Solid Tumors | High Risk Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability

Metastatic Malignant Solid Neoplasm | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Colon Adenocarcinoma | High-Frequency Microsatellite... and other conditions

United States
Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
Institut Curie

Completed

Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids (NGSKids)

Metastatic and/or High Risk Solid Tumor of Children

France
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb

Active, not recruiting

Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT)

Neuroendocrine Tumors | Advanced Biliary Tract Cancer | Female Reproductive System Neoplasm | MSI-H Solid Malignant Tumor

New Zealand, Australia
Craig L Slingluff, Jr
Theraclion

Active, not recruiting

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003)

Melanoma | Cervical Cancer | Breast Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability High | Squamous Cell Cancer

United States
Shen Lin

Not yet recruiting

An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors

To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer

China
Replimune Inc.

Recruiting

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Cancer | NSCLC | Melanoma (Skin) | Microsatellite Instability | Cutaneous Melanoma | Mismatch Repair Deficiency | Non-melanoma Skin Cancer

United States, Spain, France, United Kingdom, Germany
Massachusetts General Hospital
Bristol-Myers Squibb

Recruiting

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Pancreatic Cancer | Microsatellite Stable Colorectal Cancer | MSI High Colorectal Cancer

United States

Clinical Trials on Microsatellite Instability-High (MSI-H) Solid Tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations